Biology and Management of Patients With Triple-Negative Breast Cancer

Sharma, Priyanka

doi:10.1634/theoncologist.2016-0067

Cited by 294Breast Cancer Treatment StudiesBRCA gene mutations in cancerPARP inhibition in cancer therapy

Biology and Management of Patients With Triple-Negative Breast Cancer

Open access

Sharma, Priyanka·2016·The Oncologist

DOI 10.1634/theoncologist.2016-0067PMC PMC5016071

Open this paper in CoChat — free account Open PDF

Abstract

Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is associated with poor long-term outcomes compared with other breast cancer subtypes. Because of the lack of approved targeted therapy, at present chemotherapy remains the mainstay of treatment for early and advanced disease. TNBC is enriched for germline BRCA mutation, providing a foundation for the use of this as a biomarker to identify patients suitable for treatment with DNA-damaging agents. Inherited and acquired defects in homologous recombination DNA repair, a phenotype termed "BRCAness," may be present in a large proportion of TNBC cases, making it an attractive selection and response biomarker for DNA-damaging therapy. Triple-negative breast cancer is a diverse entity for which additional subclassifications are needed. Increasing understanding of biologic heterogeneity of TNBC has provided insight into identifying potentially effective systemic therapies, including cytotoxic and targeted agents. Numerous experimental approaches are under way, and several encouraging drug classes, such as immune checkpoint inhibitors, poly(ADP-ribose) polymerase inhibitors, platinum agents, phosphatidylinositol-3-kinase pathway inhibitors, and androgen receptor inhibitors, are being investigated in TNBC. Molecular biomarker-based patient selection in early-phase trials has the potential to accelerate development of effective therapies for this aggressive breast cancer subtype. TNBC is a complex disease, and it is likely that several different targeted approaches will be needed to make meaningful strides in improving the outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2016-0067

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The findings expand the number of TNBC patients eligible for treatment strategies targeting DNA repair mechanisms such as PARP inhibitors.
“Critically, it expands the number of TNBC patients eligible for treatment strategies targeting DNA repair mechanisms such as PARP inhibitors22,27.”
From Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study (2019) · cites this paper as [22]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Part of this paper’s reference list could not be split into single entries.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · see citing works
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382 · see citing works
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,029 · see citing works
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · see citing works
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., den Eynden, G. V., Baehner, F. L., Penault-Llorca, F. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,142 · see citing works
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,077 · see citing works
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892 · see citing works
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S. P., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,849 · see citing works
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Nielsen, T. O., Hsu, F. D., Jensen, K. C., Cheang, M. C. U., Karaca, G., Hu, Z., Hernandez‐Boussard, T., Livasy, C., Cowan, D., Dressler, L. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,665 · see citing works
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,164 · see citing works
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164 · see citing works
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F. A., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,086 · see citing works
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype
Bauer, K. R., Brown, M. M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,069 · see citing works
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · see citing works
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. K., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J. J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,889 · see citing works
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M. I., Piccart, M. J., Thürlimann, B., Senn, H.-J., André, F., Baselga, J. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,828 · see citing works
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,707 · see citing works
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655 · see citing works
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,634 · see citing works
Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1
Pratt, W., & Toft, D. (2003) · Experimental biology and medicine · doi:10.1177/153537020322800201 · Cited by 1,539 · see citing works
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,345 · see citing works
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Adams, S., Gray, R. J., Demaria, S., Goldstein, L. J., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,301 · see citing works
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,257 · see citing works
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Cheang, M. C. U., Voduc, D. K., Bajdik, C. D., Leung, S. C. Y., McKinney, S. E., Chia, S., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,197 · see citing works
Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
Haffty, B. G., Yang, Q., Reiß, M., Kearney, T. J., Higgins, S. A., Weidhaas, J. B., Harris, L. N., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,085 · see citing works
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C., Karaca, G., Nanda, R., Tretiakova, M., Olopade, O. I., Moore, D. T., & Perou, C. M. (2005) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,064 · see citing works
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Robert, N. J., Dieras, V. C., Glaspy, J. A., Brufsky, A., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,063 · see citing works
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
von Minckwitz, G., Schneeweiß, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,025 · see citing works
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Kuzma, C. S., Pluard, T., Somlo, G., Port, E. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,017 · see citing works
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szállási, Z., Li, Q., Birkbak, N. J., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 982 · see citing works
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
Kohler, B., Sherman, R., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 912 · see citing works
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X. B., Tomczak, P., Delozier, T., Sohn, J., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 896 · see citing works
Epidemiology of basal-like breast cancer
Millikan, R. C., Newman, B. M., Tse, C., Moorman, P. G., Conway, K., Smith, L. V., Labbok, M. H., Geradts, J., Bensen, J. T., Jackson, S., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9632-6 · Cited by 891 · see citing works
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith‐McCune, K., Broaddus, R. R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 818 · see citing works
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P. J., Bonnefoi, H. R., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G. M., Bergh, J. C. S., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 783 · see citing works
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Masuda, H., Baggerly, K., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobágyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 753 · see citing works
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Gucalp, A., Tolaney, S. M., Isakoff, S. J., Ingle, J. N., Liu, M., Carey, L., Blackwell, K., Rugo, H. S., Nabell, L. M., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 750 · see citing works
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Hatzis, C. (2011) · JAMA · doi:10.1001/jama.2011.593 · Cited by 699 · see citing works
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P. L., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 673 · see citing works
Self-citation
Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
Gianni, L., Zambetti, M., Clark, K., Baker, J. B., Cronin, M. T., Wu, J., Mariani, G., Rodriguez‐Canales, J., Carcangiu, M. L., Watson, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0818 · Cited by 624 · see citing works
The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors
Ghebeh, H., Mohammed, S. F., Al-Omair, A., Qattan, A. T., Lehé, C. L., Al-Qudaihi, G., Elkum, N. B., Alshabanah, M., Amer, S. M. B., Tulbah, A. M., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612 · see citing works
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 609 · see citing works
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
Doane, A. S., Danso, M. A., Lal, P., Donaton, M., Zhang, L., Hudis, C. A., & Gerald, W. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209415 · Cited by 604 · see citing works
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
Hammond, M. E. H., Hayes, D. F., Wolff, A. C., et al. (2010) · Journal of Oncology Practice · doi:10.1200/jop.777003 · Cited by 594 · see citing works
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S. S., Stemke‐Hale, K., Hennessy, B. T., Arun, B., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 574 · see citing works
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568 · see citing works
Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.166 · Cited by 566 · see citing works
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M. D., Omlin, A. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 564 · see citing works
Pattern of metastatic spread in triple-negative breast cancer
Dent, R. A., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 555 · see citing works
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F. M., Poortmans, P. M., Thompson, A. M., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479 · see citing works
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465 · see citing works
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 457 · see citing works
Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
Gewinner, C. A., Wang, Z. C., Richardson, A. L., Teruya‐Feldstein, J., Etemadmoghadam, D., Bowtell, D. D. L., Barretina, J., Lin, W. M., Rameh, L. E., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 456 · see citing works
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447 · see citing works
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L., Krag, K. J., Rugo, H. S., Liu, M., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436 · see citing works
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
Cameron, D., Brown, J. M., Dent, R. A., Jackisch, C., Mackey, J. R., Pivot, X. B., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432 · see citing works
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
von Minckwitz, G., Blohmer, J., Costa, S. D., Denkert, C., Eidtmann, H., EIERMANN, W., Gerber, B., Hanusch, C. A., Hilfrich, J., Huober, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0940 · Cited by 415 · see citing works
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. J. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354 · see citing works
Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S. M., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345 · see citing works
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332 · see citing works
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Bastien, R. R. L., Rodríguez-Lescure, Á., Ebbert, M., Prat, A., Munárriz, B., Rowe, L. R., Miller, P. A., Ruíz‐Borrego, M., Anderson, D., Lyons, B. W., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-44 · Cited by 331 · see citing works
NCCN breast cancer clinical practice guidelines in oncology: an update.
Carlson, R. W. (2003) · PubMed · Cited by 322 · see citing works
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
Tan, D. S. P., Marchiò, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318 · see citing works
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P. J., Bonnefoi, H. R., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G. M., Bergh, J. C. S., Cameron, D., Goldstein, D. R., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1122 · Cited by 307 · see citing works
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J. L., O'Toole, S. A., Millar, E. K. A., López‐Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283 · see citing works
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Leijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5991 · Cited by 266 · see citing works
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Soliman, H. H., Khalil, F. K., & Antonia, S. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088557 · Cited by 245 · see citing works
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 239 · see citing works
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1 / 2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P., Timms, K. M., Abkevich, V., Schackmann, E. A., Wapnir, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0085 · Cited by 233 · see citing works
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
Lips, E. H., Mulder, L., Oonk, A. M. M., van der Kolk, L. E., Hogervorst, F. B. L., Imholz, A. L. T., Wesseling, J., Rodenhuis, S., & Nederlof, P. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.144 · Cited by 231 · see citing works
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
Alba, E., Calvo, L., Albanell, J., de la Haba-Rodríguez, J., Lanza, A. A., Chacón, J. I., Sánchez‐Rovira, P., Plazaola, A., García‐Asenjo, J. A. L., Bermejo, B., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds132 · Cited by 229 · see citing works
Cisplatin as first-line therapy for metastatic breast cancer.
Sledge, G. W., Loehrer, P. J., Roth, B. J., et al. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1811 · Cited by 228 · see citing works
Genome-wide transcriptome profiling of homologous recombination DNA repair
Peng, G., Lin, C. C.-J., Mo, W., Dai, H., Park, Y., Kim, S. M., Peng, Y., Mo, Q., Siwko, S. K., Hu, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4361 · Cited by 223 · see citing works
Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer
Hartman, A., Kaldate, R., Sailer, L. M., Painter, L., Grier, C. E., Endsley, R. R., Griffin, M., Hamilton, S. A., Frye, C., Silberman, M. A., et al. (2011) · Cancer · doi:10.1002/cncr.26576 · Cited by 220 · see citing works
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
Marty, B., Maire, V., Gravier, E., Rigaill, G. J., Vincent‐Salomon, A., Käppler, M., Lebigot, I., Djelti, F., Tourdès, A., Gestraud, P., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2204 · Cited by 216 · see citing works
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
Loibl, S., Müller, B. M., von Minckwitz, G., Schwabe, M., Roller, M., Darb‐Esfahani, S., Ataseven, B., du Bois, A., Fissler-Eckhoff, A., Gerber, B., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1715-8 · Cited by 212 · see citing works
Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
Emens, L. A., Braiteh, F. S., Cassier, P. A., Delord, J., Eder, J. P., Fassò, M., Xiao, Y., Wang, Y., Molinero, L. L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211 · see citing works
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Byrski, T., Dent, R. A., Blecharz, P., Foszczyńska‐Kłoda, M., Gronwald, J., Huzarski, T., Cybulski, C., Marczyk, E., Chrzan, R. M., Eisen, A. F., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3231 · Cited by 210 · see citing works
The Role of the BRCA1 Tumor Suppressor in DNA Double-Strand Break Repair
Zhang, J., & Powell, S. N. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0192 · Cited by 207 · see citing works
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
Sharma, P., Klemp, J. R., Kimler, B. F., Mahnken, J. D., Geier, L. J., Khan, Q. J., Elia, M., Connor, C. S., McGinness, M., Mammen, J., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2980-0 · Cited by 202 · see citing works
Self-citation
Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates
Golshan, M. A., Cirrincione, C., Sikov, W. M., Berry, D. A., Jasinski, S., Weisberg, T., Somlo, G., Hudis, C. A., Winer, E. P., & Ollila, D. W. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001417 · Cited by 196 · see citing works
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value
Stirzaker, C., Zotenko, E., Song, J. Z., Qu, W., Nair, S. S., Locke, W. J., Stone, A. M., Armstong, N. J., Robinson, M. D., Dobrovic, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms6899 · Cited by 188 · see citing works
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
Tutt, A. N. J., Ellis, P., Kilburn, L. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s3-01 · Cited by 169 · see citing works
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
Baselga, J. M., Segalla, J. G. M., Roche, H. H., del Giglio, A., Pinczowski, H., Ciruelos, E., Filho, S. C., Gómez, P., Eyll, B. V., Bermejo, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7771 · Cited by 165 · see citing works
Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
Ha, K., Fiskus, W. C., Choi, D. S., Bhaskara, S., Cerchietti, L. C. A., Devaraj, S. G. T., Shah, B., Sharma, S., Chang, J. C., Melnick, A. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2154 · Cited by 157 · see citing works
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
Swain, S. M., Tang, G., Geyer, C. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1275 · Cited by 145 · see citing works
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation
Stecklein, S. R., Kumaraswamy, E., Behbod, F., Wang, W., Chaguturu, V., Harlan-Williams, L. M., & Jensen, R. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203326109 · Cited by 135 · see citing works
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Rugo, H. S., Rivera, R., Duenne, A., Bousfoul, N., & Yardley, D. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2008-6 · Cited by 132 · see citing works
Triple-Negative Breast Cancer
Gucalp, A., & Traina, T. A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181ce4ae1 · Cited by 131 · see citing works
International Adaptations of NCCN Clinical Practice Guidelines in Oncology
Carlson, R. W., Larsen, J. K., McClure, J. S., Fitzgerald, C. L., Venook, A. P., Benson, A. B., & Anderson, B. O. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0068 · Cited by 131 · see citing works
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
Watkins, J. A., Weekes, D. B., Shah, V., Gazińska, P., Joshi, S. P., Sidhu, B., Gillett, C., Pinder, S. E., Vanoli, F., Jasin, M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1092 · Cited by 120 · see citing works
Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Dolled-Filhart, M. P., Emancipator, K., Gonzalez, E. J., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s1-09 · Cited by 114 · see citing works
Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
Mulligan, J. M., Hill, L. A., Deharo, S., Irwin, G. W., Boyle, D., Keating, K. E., Raji, O. Y., McDyer, F. A., O’Brien, E. J., Bylesjö, M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt335 · Cited by 113 · see citing works
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Wesseling, J., van de Vijver, M. J., de Vries, E. G. E., van Tinteren, H., Jonkers, J., Hauptmann, M., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3655 · Cited by 111 · see citing works
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
Rossari, J. R. F., Metzger, O., Paesmans, M., Saini, K. S., Gennari, A., de Azambuja, E., & Piccart, M. J. (2012) · Journal of Oncology · doi:10.1155/2012/417673 · Cited by 102 · see citing works
Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)
Sikov, W. M., Berry, D., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Somlo, G., Port, E., Qamar, R., Sturtz, K. B., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s2-05 · Cited by 85 · see citing works
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients
Hurley, J., Reis, I. M., Rodgers, S. E., Gomez-Fernandez, C., Wright, J., Leone, J. P., Larrieu, R., & Pegram, M. D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2497-y · Cited by 83 · see citing works
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy
Lips, E. H., Mulder, L., Hannemann, J., Laddach, N., Peeters, M.-J. T. F. D. V., van de Vijver, M. J., Wesseling, J., Nederlof, P. M., & Rodenhuis, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq468 · Cited by 81 · see citing works
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
Ando, M., Yamauchi, H., Aogi, K., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2947-1 · Cited by 77 · see citing works
Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients
Ring, B. Z., Hout, D. R., Morris, S. W., Lawrence, K. D., Schweitzer, B. L., Bailey, D. B., Lehmann, B. D., Pietenpol, J. A., & Seitz, R. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2198-0 · Cited by 75 · see citing works
Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
Rugo, H., Olopade, O., DeMichele, A. M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-s5-02 · Cited by 73 · see citing works
Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
Brazelle, W., Kreahling, J. M., Gemmer, J. Y., Ma, Y., Cress, W. D., Haura, E. B., & Altiok, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014335 · Cited by 70 · see citing works
Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
von Minckwitz, G., Loibl, S., Schneeweiß, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s2-04 · Cited by 62 · see citing works
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.
von Minckwitz, G., Hahnen, E., Fasching, P. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.1005 · Cited by 61 · see citing works
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer
Sharma, P., Stecklein, S. R., Kimler, B. F., Sethi, G., Petroff, B. K., Phillips, T. A., Tawfik, O. W., Godwin, A. K., & Jensen, R. A. (2014) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-3-2 · Cited by 58 · see citing works
Self-citation
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv241 · Cited by 48 · see citing works
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
Prat, A., Cruz, C., Hoadley, K. A., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3056-x · Cited by 47 · see citing works
Molecular Pathways: Old Drugs Define New Pathways: Non-Histone Acetylation at the Crossroads of the DNA Damage Response and Autophagy
Botrugno, O. A., Robert, T., Vanoli, F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0767 · Cited by 40 · see citing works
A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
Leijen, S., Schellens, J. H. M., Shapiro, G. I., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3067 · Cited by 35 · see citing works
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Santarosa, M., Col, L. D., Tonin, E., Caragnano, A., Viel, A., & Maestro, R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0951 · Cited by 33 · see citing works
Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors
Kolarić, K., Roth, A., Jelicić, I., et al. (1982) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00406247 · Cited by 27 · see citing works
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
Weberpals, J. I., O'Brien, A. M., Niknejad, N., et al. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-29 · Cited by 22 · see citing works
Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response
Kern, P., Kalisch, A., Kolberg, H., Kimmig, R., Otterbach, F., von Minckwitz, G., Sikov, W. M., Pott, D., & Kurbacher, C. M. (2013) · Chemotherapy · doi:10.1159/000362756 · Cited by 21 · see citing works
Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).
Pahuja, S., Beumer, J. H., Appleman, L. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.26_suppl.135 · Cited by 20 · see citing works
Abstract P1-11-07: Results of a Phase II Study of Neoadjuvant Platinum/Taxane Based Chemotherapy and Erlotinib for Triple Negative Breast Cancer
Sharma, P., Khan, Q., Kimler, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-p1-11-07 · Cited by 19 · see citing works
Self-citation
Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer
Connor, C. S., Kimler, B. F., Mammen, J. M. V., et al. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23790 · Cited by 11 · see citing works
Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC).
Sharma, P., Stecklein, S. R., Kimler, B. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.1022 · Cited by 11 · see citing works
Self-citation
Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.
Tamura, K., Hashimoto, J., Tsuda, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.1017 · Cited by 9 · see citing works
Tumor homologous recombination deficiency assays: another step closer to clinical application?
Stecklein, S. R., & Sharma, P. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0409-7 · Cited by 8 · see citing works
Self-citation
Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the randomized phase III SUCCESS-A study.
Janni, W., Schneeweiß, A., Haeberle, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.1010 · Cited by 7 · see citing works
Abstract P6-05-10: Association between BRCA1/2 status and DNA-based assays for homologous recombination deficiency in breast cancer
Timms, K., Abkevich, V., Neff, C. D., Morris, B., Potter, J., Tran, T., Chen, J., Sangale, Z., Tikishvili, E., Zharkikh, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-p6-05-10 · Cited by 6 · see citing works
TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC).
Yardley, D. A., Bosserman, L. D., Keaton, M. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1000 · Cited by 5 · see citing works
Abstract PD09-02: BRCA1 insufficiency is predictive of superior survival in patients with triple negative breast cancer treated with platinum based chemotherapy
Sharma, P., Stecklein, S. R., Kimler, B., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-pd09-02 · Cited by 4 · see citing works
Self-citation
Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxane-epirubicin in patients with locally advanced triple-negative breast cancer.
Wang, J., Xu, B., Li, Q., Zhang, P., Yuan, P., Ma, F., Fan, Y., Luo, Y., Cai, R., & Li, Q. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.1105 · Cited by 3 · see citing works

Flagged first, then by citations

Research works printed but not linked: 3

Miller K, O'Neill AM, Dang CT etal. Bevacizumab (Bv) in the adjuvant treatment of HERr2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 2014;32:500a.
Gluz O, Nitz U, Liedtke C et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Cancer Res 2016;15:S6-07.
Von Minckwitz G, Loibl S, Schneeweiss A et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadju- vanttherapyfor triple-negativeandHER2-positiveearly breast cancer (GeparSixto). Presented at the 2015 San Antonio Breast Cancer Symposium; December 8-12, 2015;

Sorted by citations

Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874 · see citing works
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307 · see citing works
Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression
Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102190 · Cited by 243 · see citing works
Multifunctional Au Modified Ti 3 C 2 -MXene for Photothermal/Enzyme Dynamic/Immune Synergistic Therapy
Chang, X., Wu, Q., Wu, Y., Xi, X., Cao, J., Chu, H., Liu, Q., Li, Y., Wu, W., Fang, X., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03260 · Cited by 109 · see citing works
FR58P1a; a new uncoupler of OXPHOS that inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway
Urra, F. A., Muñoz, F., Córdova-Delgado, M., Ramírez, M. P., Peña-Ahumada, B., Rios, M., Cruz, P., Ahumada-Castro, U., Bustos, G., Silva-Pavez, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31367-9 · Cited by 69 · see citing works

Clinicopathologic Characteristics and Prognosis of Early Stage Triple Negative Breast Cancer: Comparison with Non-triple Negative Group
Ahn, J. S., Cho, J., Kwon, S. Y., et al. (2009) · Journal of the Korean Surgical Society · doi:10.4174/jkss.2009.77.1.37 · Cited by 3 · see citing works
Supplementary Table 3 from Triple-Negative versus Non–Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study
Podo, F., Santoro, F., Leo, G. D., et al. (2023) · doi:10.1158/1078-0432.22460277
Treatment of triple negative breast cancer
Liang, J.-P., & Zhang, X. (2013) · Guoji zhongliuxue zazhi · doi:10.3760/cma.j.issn.1673-422x.2013.09.013
REVIEW ON POTENTIAL TARGETED THERAPY FOR TRIPLE NEGATIVE BREAST CANCER
Aminuddin, N. I., Edros, R. Z., & Kutty, R. V. (2020) · Journal of Chemical Engineering and Industrial Biotechnology · doi:10.15282/jceib.v5i2.3686
Triple-Negative Breast Cancer and the Potential for Targeted Therapy
Jhan, J.-R., & Andrechek, E. R. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0117 · Cited by 203 · see citing works

Authors: Sharma, P.
Affiliations: University of Kansas Medical Center (US)
Corresponding author: Sharma, Priyanka
ORCID: Sharma, Priyanka
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2016-07-11
Volume: 21
Issue: 9
Pages: 1050-1062
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2016-0067
PMC: PMC5016071
OpenAlex: W2469627334
Cited by: 294
References: 135
Citations by year: 2026: 10 · 2025: 27 · 2024: 32 · 2023: 33 · 2022: 50 · 2021: 52 · 2020: 31 · 2019: 21 · 2018: 19 · 2017: 13 · 2016: 6
FWCI: 1.79
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: triple-negative breast cancer, germline BRCA1/2 mutation, BRCAness, homologous recombination deficiency, DNA-damaging agents, platinum agents, PARP inhibitors, immune checkpoint inhibitors, PI3K inhibitors, androgen receptor antagonists, molecular subtyping, targeted therapy, biomarker-based patient selection, chemotherapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, DNA Damage, Female, Humans, Biomarkers, Tumor, Germ-Line Mutation, BRCA1 Protein, Angiogenesis Inhibitors, BRCA2 Protein, Molecular Targeted Therapy, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biology and Management of Patients With Triple-Negative Breast Cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks